iHub News
3月前
Acumen Secures Funding to Advance Enhanced Brain Delivery ProgramMarch 16, 2026 11:25 AM
IH Market News
Acumen Pharmaceuticals (NASDAQ:ABOS) announced that on March 13, 2026 it agreed to sell 10,833,331 common shares at a price of $3.30 each in a private placement with institutional accredited investors. The transaction is expected to generate gross proceeds of roughly $35.75 million, which the company plans to use to support development of its Enhanced Brain Delivery (EBD) program as well as general corporate activities.The financing, led by RA Capital Management, is scheduled to close on or around March 16, 2026. The agreement includes standard purchase and registration rights provisions and places temporary limitations on the company’s ability to issue additional shares.Separately, on March 16, 2026, the company reported new preclinical findings from its transferrin-receptor-targeting EBD platform, which is being developed in collaboration with JCR Pharmaceuticals using its J-Brain Cargo technology. Data from in vitro studies, in vivo models, and non-human primate testing showed brain exposure levels between 14 and 40 times higher than those achieved with conventional antibodies, while also demonstrating a low risk of anemia and stability compatible with subcutaneous administration.Acumen plans to submit an Investigational New Drug (IND) application for its lead EBD clinical candidate by mid-2027. The company believes the platform could help establish a differentiated—and potentially best-in-class—approach within the competitive field of antibody therapies for Alzheimer’s disease, while the new capital provides a clearer funding path to advance its pipeline.More about Acumen PharmaceuticalsAcumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target toxic soluble amyloid beta oligomers, which are believed to play a key role in Alzheimer’s disease.Based in Newton, Massachusetts, the company is currently advancing its lead monoclonal antibody candidate, sabirnetug, in a Phase 2 clinical trial. It is also developing next-generation delivery approaches, including subcutaneous formulations and enhanced brain delivery systems, through collaborations such as its partnership with JCR Pharmaceuticals.Acumen’s research strategy centers on oligomer-selective antibodies and advanced delivery technologies designed to improve drug penetration into the central nervous system and enable more convenient dosing for patients. The company aims to develop disease-modifying treatments for early symptomatic Alzheimer’s disease, positioning itself within a rapidly evolving and highly competitive neurodegenerative therapy market.Acumen Pharmaceuticals stock price
Original: Acumen Secures Funding to Advance Enhanced Brain Delivery Program
stockrafter
3月前
Yes that is a good presentation. The thing with Acumen presentations, and articles, are that they so well written. Shows they really know what they are talking about and know what needs to be done to bring Sabirnetug to the market.
Investors can expect update progress on several ongoing issues, such as an update on Enhance Brain Delivery progress with JCR, notice of the annual report, and upcoming AP/AD conference, an who knows what else..
Wow the constant pop up window while typing is irritating as heck. Nasty people gotta constantly shove stuff in your face.
stockrafter
3月前
From reading the two articles posted earlier, it is obvious where this thing is going.
Looking at the chart on Yahoo, the share price started moving up after the two articles were posted, "Coincidence or what?"
Recently a couple serious scientific publications in, Lancet Neurology, on the future of Alzheimer appears to be generating a lot of interest in Acumen and its Sabirnetug.
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00055-4/abstract
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00045-1/fulltext
stockrafter
5月前
Something that makes ABOS extra exciting is this article another investor sent me...
https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
What mega pharma company would not want to buy ABOS when they report stellar results from the P2 Sabirnetug trial in Oct, along with two "Enhanced Brain Delivery" drugs. EBD increases delivery of Sabirnetug to the brain around 50X.
Think about it, at 62 million shares OS at $100/share, that only makes it $6.2 billion for a proven ALS drugs, and two other potential block busters EBD drugs...........do I hear $200...........
Come on, by October, ABOS will put the chart of this stock, posted on the yahoo site, to shame...... https://finance.yahoo.com/quote/TERN/
Excited yet?
SR
stockrafter
5月前
And it appears the MM are taking advantage of the sells, because, IMO, they know the upcoming PR investors are expecting in the near future will be EXPLOSIVE, when we learn what is ACU-234, and the two JCR BBB drug combos.
How could an investor not be excited about ABOS........Get on board while the getting is cheap, and enjoy the rafting till Oct, when the ride turns into a rocket.........
SR
stockrafter
7月前
Expect investors should learn a little bit more on JCR BBB deal from the Q3 report and CC in a couple of weeks. And agree, the information should be interesting. A quick search on JCR Blood-Brain Barrier, shows JCR is signing a lot of new deals, and has had some recent success and approvals. The science of the BBB is very complex and to break thru BBB with sabirnetug should be very beneficial to the delivery.
As Dan says it in the Q2 report... “This collaboration with JCR allows us to explore a powerful new approach to delivering therapies directly to the brain,” Acumen CEO Daniel O’Connell said in the July 15 release. “By pairing our AßO-selective antibody expertise with JCR’s J-Brain Cargo platform, we have the potential to advance a differentiated therapeutic that could change the treatment paradigm for people living with Alzheimer’s disease.”
Should give us investors something to discuss while waiting for the P2/3 trial report in late Oct 2026, along with watch the share price steadily rising....
Student of the Game
7月前
Just a reminder from this July 15th JCR press release…….
Collaboration Details and Next Steps
Acumen and JCR have collaborated for more than a year conducting feasibility work to assess the combination of JCR’s transferrin targeting technology with Acumen’s AßO-targeting antibodies.
JCR’s transferrin receptor binding platform includes a library of both scFv (single chain variable fragment antibodies) and VHHs (variable heavy domain antibodies), molecules related to the full IgG used in their approved therapy, IZCARGO®.
In addition to sabirnetug, the collaboration is also investigating other oligomer-specific antibodies in Acumen’s library to further establish lifecycle opportunities.
A preclinical candidate (PCC) data package, inclusive of a non-human primate study, is expected in early 2026, at which point Acumen has an exclusive right to exercise its option to develop up to two development candidates.
Clearly; the non-human primate study is ongoing and being evaluated. The PCC will be ready in EARLY 2026. So far, Acumen has not been late on any timeline, so I would expect this non-human primate study in Q1. This IMO, could be VERY interesting news!!
stockrafter
9月前
Will certainly be listening in today....
Hope it is more than his latest conversation, good stuff, but nothing new, need stuff on BBB drug, SC AI trial, P2 progress, financing deals.......
"Alzheimer's Trial Targeting Amyloid Beta Oligomers Sees Cost Savings, Patient Satisfaction With New Screening"
https://www.clinicalleader.com/doc/alzheimer-s-trial-targeting-amyloid-beta-oligomers-sees-cost-savings-patient-satisfaction-with-new-screening-0001
Biogen got their SC-AI thru the system for Leqembir...
https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous
stockrafter
10月前
Nothing new, but it is the CMO, so worth a watch, while waiting for the buying to starts in masses............
This just sounds impressive......"8750-fold"........"Surface plasmon resonance testing revealed that sabirnetug binds ß-amyloid oligomers with an 8750-fold selectivity over abundant monomeric ß-amyloid forms, outperforming other monoclonal antibodies such as lecanemab (Leqembi; Eisai) and aducanumab (Aduhelm; Eisai/Biogen)."
Commentary
Video
August 13, 2025
Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD
https://www.neurologylive.com/view/advances-ad-screening-antibody-therapy-aaic-2025-eric-siemers?utm_content=343031360&utm_medium=social&utm_source=twitter&hss_channel=tw-1016356467073585152
stockrafter
10月前
Sell off has always been perplexingly irrational to me......
MMs take advantage of any weakness on any "bad" news, and pick off those "stop orders" on the way down. IMO, the price should at least be in the 3-4 buck range while waiting for the top-line P2 clinical results....but 11 buck would be nice as the AI generated story claims.....
https://ph.investing.com/news/analyst-ratings/acumen-pharmaceuticals-stock-maintains-buy-rating-at-btig-on-promising-alzheimers-drug-93CH-1956067
Agree thought the CC was good, of course cost went up from previous Qs, they are running a P2 clinical trial. Mgt again stated there is enough cash to run the P2 trial, and into 2027, at current cash reserves. BUT....suspect there will be new cash inflows from interested parties, one way or another, without dilution, such as the potential for an interesting SC AI deal.....a lot of cash sitting over there........
Looked up the big word from the CC, interesting....."Mechanisms of receptor-mediated transcytosis at the blood-brain barrier"
https://www.sciencedirect.com/science/article/pii/S0168365925002044
stockrafter
10月前
Looked into the interesting comment at end of JCR PR.........
"Acumen holds exclusive rights to develop up to two development candidates."
Sabirnetug is one, what is the other..........It is another exciting Alz drug, an APP modulator....
"What are APP modulators and how do they work?"
https://synapse.patsnap.com/article/what-are-app-modulators-and-how-do-they-work?
"In conclusion, APP modulators represent a promising area of research with the potential to revolutionize the treatment of neurodegenerative diseases. By targeting the early stages of disease pathology, these compounds offer hope for more effective therapies. As research progresses, it is anticipated that APP modulators will become an integral part of the therapeutic arsenal against neurodegenerative disorders."
stockrafter
11月前
Should at least be in the 4-5 buck range till it moves up to 10-20 range before P2 trial update in Oct 2026, in my nontechnical opinion....
The things they do not tell investors......who knew they were working on the feasibility for over a year.
"The deal terms are favorable, having been finalized after a year of feasibility studies and structured to be largely backloaded, which minimizes immediate financial impact."
Back-loading is good, and assuring the money last until end of P2 trial. By then they will need money, which is either thru dilution or partners...When they publish the exceptional P2 results, the share price will much higher, so dilution will be minimal, and a partner with money, will be knocking. As noted in the article..
"The upfront costs are minimal, and the potential milestone payments are expected to occur after 2026, aligning with Acumen’s financial projections. Furthermore, the collaboration could enhance the clinical profile of Acumen’s assets and provide additional news flow, potentially acting as catalysts ahead of key readouts, thereby maintaining a compelling risk/reward profile for the stock."
For kicks looked up the TM, it was recently filed on July 8.
https://tsdr.uspto.gov/#caseNumber=+%0999272511&caseSearchType=US_APPLICATION&caseType=SERIAL_NO&searchType=statusSearch
Student of the Game
11月前
CITI's Research comments to Tuesday's press release..
Acumen’s collaboration with JCR Pharma leverages strengths and provides pipeline optionality
CITI’S TAKE Acumen announced a collaboration this morning with JCR Pharma in Alzheimer’s disease. The collaboration is focused on oligomer-targeted enhanced brain delivery therapy, which combines Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor approach to penetrating the blood-brain barrier. Initial preclinical data is expected in early 2026, at which Acumen has the exclusive right to exercise its option to develop up to two development candidates. In our view, this collaboration looks to be a big positive given technology synergy; the collaboration bodes well for Acumen by adding to the pipeline in a capital efficient way. While we note data are still some time away, we remain cautiously optimistic given higher pipeline optionality but in a high risk / high reward indication like AD. Maintain Buy/HR and $4 TP.
More about JCR’s technology – JCR’s transferrin receptor binding platform includes a library of both scFv (single chain variable fragment antibodies) and VHHs (variable heavy domain antibodies), molecules related to the full IgG used in IZCARGO, which is an approved therapy for Hunter syndrome.
Financial details of the collaboration – Under the terms of the agreement, JCR will receive an upfront payment and will be eligible for an additional option payment of $9.25 million should Acumen exercise its exclusive option to develop up to two development candidates. JCR will also be eligible to receive future milestone payments of up to $40 million related to development, and up to $515 million related to sales, for a total of up to $555 million, as well as single-digit percentage royalties on sales of any products that emerge from the collaboration.
Upcoming catalysts for Acumen – From this collaboration, Acumen expects preclinical in early 2026 for its oligomer-targeted enhanced delivery program for AD. The company also remains on track to report phase 2 (ALTITUDE-AD) topline results of sabirnetug for AD in late 2026.
stockrafter
11月前
Agree, nice summary, and definitely POSITIVE news for ABOS.......
The interesting part was how much money JCR receives...which leads to, if they are going to make so much, how much will ABOS make? It has to be a lot.......
Side issue, in the PR for the presentations, they wrote, "The conference will be held July 27-31, 2025, both in-person and online."....Wonder if investors can watch it online? ......Will need to look into that.....
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
3月前
TrendTrade2016
4月前
メールアドレスで登録
